Details of the Drug Reposition

General Information of This Drug (ID: DMSWNJF)

Drug Name
Ravulizumab   DMSWNJF
Synonyms Ravulizumab [USAN]; UNII-C3VX249T6L; C3VX249T6L; ALXN1210
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Paroxysmal nocturnal haemoglobinuria DISBHMYH 3A21.0 Approved [1]
------------------------------------------------------------------------------------
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 3 [2]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 761108.
2 ClinicalTrials.gov (NCT04369469) Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia. U.S. National Institutes of Health.